Pihlajalinna Oyj (FRA:38P) Research & Development: €0.0 Mil (TTM As of Mar. 2026)


FRA:38P Pihlajalinna Oyj FRA:38P
72 GF Score
Price €10.26
GF Value €8.89
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Pihlajalinna Oyj Research & Development?

Pihlajalinna Oyj FRA:38P -0.39% 72 Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:38P with a GF Score™ of 72/100 and a GF Value™ of €8.89 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pihlajalinna Oyj's Research & Development for the three months ended in Mar. 2026 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Pihlajalinna Oyj  (FRA:38P) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pihlajalinna Oyj Research & Development Related Terms

Pihlajalinna Oyj Research & Development Historical Data

* Premium members only.

The historical data trend for Pihlajalinna Oyj's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pihlajalinna Oyj Research & Development Chart

Pihlajalinna Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pihlajalinna Oyj Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:38P
72GF Score
Pihlajalinna Oyj FRA:38P
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pihlajalinna Oyj Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Pihlajalinna Oyj (FRA:38P) has a Research & Development of €0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pihlajalinna Oyj and its competitors.
Is Pihlajalinna Oyj's Research & Development too high?
Pihlajalinna Oyj's current Research & Development is €0.0 Mil. Overall, Pihlajalinna Oyj has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pihlajalinna Oyj's Research & Development compare to HCA and THC?
Pihlajalinna Oyj's Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pihlajalinna Oyj and its competitors. Pihlajalinna Oyj's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pihlajalinna Oyj stock overvalued right now?
Based on GuruFocus' analysis, Pihlajalinna Oyj (FRA:38P) is currently considered Modestly Overvalued. The stock's GF Value™ is €8.89, compared to a current price of €10.26 — trading 15.4% above its estimated fair value. The current Research & Development is €0.0 Mil. Pihlajalinna Oyj's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pihlajalinna Oyj (FRA:38P), the current Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pihlajalinna Oyj (FRA:38P) Overvalued in 2026?

Based on GuruFocus' analysis, Pihlajalinna Oyj stock appears to be overvalued. The current stock price of €10.26 is trading 15.4% above its estimated GF Value™ of €8.89. GuruFocus considers Pihlajalinna Oyj to be Modestly Overvalued.

Key valuation signals for FRA:38P:

  • Research & Development: €0.0 Mil
  • GF Value™: €8.89 vs. price of €10.26 (15.4% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the FRA:38P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pihlajalinna Oyj Business Description

Address Kehrasaari B, Tampere, FIN, FI-33200
Pihlajalinna Oyj is a private social and healthcare service providers in Finland. It provides comprehensive, high-quality services through private clinics, hospitals, remote channels, occupational healthcare, and tailored social and healthcare solutions for the public sector. It has two reportable segments: Private Healthcare Services and Public Services. The Private Healthcare Services operating segment consists of private clinic, diagnostics, hospital, occupational healthcare, remote and fitness center services. The Public Services operating segment consists of social and healthcare services produced for the public sector, which include outsourcing and housing services, mainly remotely produced responsible doctor services, as well as a wide range of staffing and recruitment services.
72GF Score

Get the complete analysis for FRA:38P

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.26
Price
€8.89
GF Value